Work

Dose escalation results from a first-in-human, phase 1 study of the glucocorticoid-induced TNF receptor-related protein (GITR) agonist AMG 228 in patients (Pts) with advanced solid tumors.

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.2521

Authors: Ben Tran, Richard D. Carvajal, Aurelien Marabelle, Sandip P. Patel, Patricia LoRusso, Erik Rasmussen, Gloria Juan, Vijay V. Upreti, Gataree Ngarmchamnanrith, Patrick Schöffski

Institutions: Peter MacCallum Cancer Centre, Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center, Columbia University, Université Paris-Saclay, Institut Gustave Roussy, Moores Cancer Center, Yale Cancer Center, Yale University, Amgen (United States), Universitair Ziekenhuis Leuven

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2632616587

Cites:

Cited by: 11

Related to: 10